NCT04303988: A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.

NCT04303988
Breast Cancer Type: HER2+, Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic antibody, Immunotherapy, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with HR+ breast cancer; Patients with TNBC who have received prior therapy of platinum drugs (e.g. cisplatin, carboplatin); Patients with HER2+ breast cancer who have received prior therapy of anti-HER2 tyrosine-kinase inhibitors (e.g. neratinib, lapatinib, tucatinib). Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04303988

Comments are closed.

Up ↑